What is Suda?
SUDA is dedicated to pioneering a novel, first-in-class therapeutic strategy for cancer treatment, centered on the drug anagrelide. Beyond its oncology pipeline, the company is advancing its short-term insomnia treatment, ZolpiMist, awaiting regulatory feedback from the TGA in Q4 2020. SUDA also engages in collaborative product development with established partners including Sanofi, Strides Pharma Global, Laboratorios Ordesa, Zelira Therapeutics, and Cann Pharmaceutical Australia, indicating a diversified approach to drug development and commercialization.
How much funding has Suda raised?
Suda has raised a total of $2.7M across 1 funding round:
Share Placement
$2.7M
Share Placement (2020): $2.7M, investors not publicly disclosed
What's next for Suda?
The recent major strategic investment positions Suda for accelerated growth and the advancement of its key therapeutic programs. With a focus on both oncology and insomnia treatments, alongside strategic partnerships, the company appears poised to navigate complex regulatory pathways and market entry. Future developments will likely involve clinical trial progression, potential regulatory approvals, and the expansion of its product portfolio, leveraging the recent capital to solidify its market presence and therapeutic impact.
See full Suda company page
